| Aetna | Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries | 2025-10-02 |
| Medical Mutual | Amtagvi® (lifileucel) (Intravenous) | 2025-10-02 |
| Medical Mutual | Azedra® (iobenguane I-131) (Intravenous) | 2025-10-02 |
| Medical Mutual | Emrelis™ (telisotuzumab vedotin-tllv) (Intravenous) | 2025-10-02 |
| Medical Mutual | Encelto™ (revakinagene taroretcel-lwey) (Intravitreal) | 2025-10-02 |
| Medical Mutual | Fyarro® (sirolimus albumin-bound) (Intravenous) | 2025-10-02 |
| Medical Mutual | Leuprolide Suspension: Camcevi®, Camcevi ETM®, Eligard®, Fensolvi®, Leuprolide (Intramuscular/Subcutaneous) | 2025-10-02 |
| Medical Mutual | Lutathera® (lutetium Lu 177 dotatate) (Intravenous) | 2025-10-02 |
| Medical Mutual | Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) (Intravenous) | 2025-10-02 |
| Medical Mutual | Tecelra® (afamitresgene autoleucel) (Intravenous) | 2025-10-02 |